AT THE 2025 Prefontaine Classic, a sold-out crowd of 12,606 was treated to two profound demonstrations of human potential on ...
A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...
Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results